- Bloomberg: Greg Wasson joins thought leaders to discuss the state of health care in the United States
- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- CVS Caremark aims to help customers as survey spotlights ACA knowledge gap
- State of the market: Are generic drugs approaching their peak?
- CVS Caremark's Merlo attends reception to accept March of Dimes Citizen of the Year award
NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.
B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well.
Other companies who have been invited to bid include Merck and Pfizer.
For the full story, click here.
Find us on Facebook for more information on drug store news, insights and products.